Study confirms risk from swine flu vaccine

Paris - A French study on the swine flu vaccine Pandemrix has confirmed an increased risk of developing post-vaccination in the sleep disorder narcolepsy. The also used in Germany for fear of the swine flu vaccine increases the risk not only for children and young people, but also in adults, raising the coordinator of the study, Antoine Pariente forth. In Finland and Sweden studies had previously pointed to an increased risk of narcolepsy.


The new French study published in Stockholm, according to the risk for people under 19 increased by five times, for older people by a factor of 3.5. Narcolepsy is a sleep disorder that is manifested by the fact that daytime sleepiness is a strong and uncontrollable sleep phases used. The rare disease may be accompanied by sudden Muskelerschlaffungen.
The vaccine Pandemrix the British manufacturer GlaxoSmithKline had been used for fear of a swine flu epidemic and for the general population in Germany. It contains reinforcing additives, so-called adjuvants, which make the vaccine more effective, but can also lead to increased side effects. The states were left to sit on a large part of the vaccine because not as many people were as expected vaccinated against swine flu. The surplus vaccine had to be destroyed at the end.
In France, of the health authorities to Thursday 51 narcolepsy cases registered in vaccinated patients, 47 of which were vaccinated with Pandemrix. The swine flu had spread from Mexico in early 2009 from all over the world. In June 2009 the World Health Organization (WHO) finally called from a pandemic that she declared in August 2010 after the ebbing of the flu season was over.